Should You Stop Using Nimesulide Above 100mg? Telangana Drugs Control Administration Warns
Synopsis
Key Takeaways
Hyderabad, Dec 31 (NationPress) The Drugs Control Administration in Telangana has urgently recommended that individuals cease the use of all oral formulations containing Nimesulide exceeding 100 milligrams in immediate release dosage form, effective immediately.
This public advisory follows a directive from the Union Ministry of Health and Family Welfare, which has banned the manufacture, sale, and distribution of all oral formulations with Nimesulide above 100 mg for human consumption, effective immediately.
Nimesulide, recognized as a non-steroidal anti-inflammatory drug, has been scrutinized globally due to concerns regarding potential liver toxicity and other harmful effects.
Patients currently on such medications are urged to stop use and consult a qualified Registered Medical Practitioner for safer alternatives, as stated by Shahnawaz Qasim, the Director General of the Drugs Control Administration.
The public is advised against purchasing, using, or storing these banned formulations under any circumstances.
This prohibition is enforced due to the potential risks to human health associated with these formulations, especially when safer alternatives are available.
The Drugs Control Administration is actively working to remove these products from the market and supply chain throughout the state. Public cooperation is essential for maintaining health and safety standards. Should any prohibited formulations be found for sale or distribution, individuals are encouraged to report this to the nearest Drugs Inspector or Drugs Control Administration office.
The ban was implemented under Section 26A of the Drugs and Cosmetics Act, 1940, following consultations with the Drugs Technical Advisory Board. This initiative is part of broader efforts to enhance safety standards and phase out high-risk medications.
Companies producing Nimesulide brands are required to stop production and recall affected batches.
This restriction applies solely to high-dose products intended for human use, while lower-dose formulations and alternative therapies will remain accessible.